STOCK TITAN

Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Takeda and Boston Medical Center (BMC) announced a three-year collaboration to reduce greenhouse gas emissions in healthcare, focusing on regulated medical waste and pharmaceutical packaging. The initiative aims to identify and pilot decarbonization solutions that can be shared across the healthcare ecosystem. BMC will conduct waste audits in clinical areas to identify emission hotspots and test new technologies. This partnership supports Takeda's goal to achieve net-zero emissions in operations by 2035 and across its value chain by 2040, recently validated by the Science Based Targets initiative.

Takeda e Boston Medical Center (BMC) hanno annunciato una collaborazione triennale per ridurre le emissioni di gas serra nel settore sanitario, concentrandosi sui rifiuti medici regolamentati e sull'imballaggio farmaceutico. L'iniziativa mira a identificare e testare soluzioni di decarbonizzazione da condividere nell'ecosistema sanitario. BMC condurrà audit sui rifiuti nelle aree cliniche per identificare i punti critici delle emissioni e testare nuove tecnologie. Questa partnership supporta l'obiettivo di Takeda di raggiungere emissioni nette pari a zero nelle operazioni entro il 2035 e lungo l'intera catena del valore entro il 2040, recentemente convalidato dall'iniziativa Science Based Targets.

Takeda y Boston Medical Center (BMC) anunciaron una colaboración de tres años para reducir las emisiones de gases de efecto invernadero en el cuidado de la salud, enfocándose en los residuos médicos regulados y el empaquetado farmacéutico. La iniciativa tiene como objetivo identificar y probar soluciones de descarbonización que se pueden compartir en todo el ecosistema de la salud. BMC llevará a cabo auditorías de residuos en áreas clínicas para identificar puntos críticos de emisión y probar nuevas tecnologías. Esta asociación apoya el objetivo de Takeda de lograr emisiones netas cero en sus operaciones para 2035 y en toda su cadena de valor para 2040, recientemente validado por la iniciativa Science Based Targets.

타케다보스턴 메디컬 센터(BMC)는 의료 분야에서 온실가스 배출을 줄이기 위해 규제된 의료 폐기물과 제약 포장에 중점을 둔 3년간의 협력을 발표했습니다. 이 이니셔티브는 의료 생태계 전반에 걸쳐 공유할 수 있는 탈탄소화 솔루션을 식별하고 테스트하는 것을 목표로 합니다. BMC는 임상 분야에서 폐기물 감사를 수행하여 배출 핫스팟을 식별하고 새로운 기술을 테스트할 것입니다. 이 파트너십은 2035년까지 운영에서 제로 탄소 배출을 달성하고 2040년까지 가치 사슬 전반에 걸쳐 이를 달성하겠다는 타케다의 목표를 지원하며, 이는 최근 Science Based Targets 이니셔티브에 의해 검증되었습니다.

Takeda et Boston Medical Center (BMC) ont annoncé une collaboration de trois ans pour réduire les émissions de gaz à effet de serre dans le secteur de la santé, en se concentrant sur les déchets médicaux réglementés et l'emballage pharmaceutique. L'initiative vise à identifier et à tester des solutions de décarbonisation à partager au sein de l'écosystème de la santé. BMC effectuera des audits des déchets dans les zones cliniques pour identifier les points chauds d'émission et tester de nouvelles technologies. Ce partenariat soutient l'objectif de Takeda d'atteindre des émissions nettes nulles dans ses opérations d'ici 2035 et dans toute sa chaîne de valeur d'ici 2040, récemment validé par l'initiative Science Based Targets.

Takeda und Boston Medical Center (BMC) haben eine dreijährige Zusammenarbeit angekündigt, um die Treibhausgasemissionen im Gesundheitswesen zu reduzieren, mit Schwerpunkt auf regulierten medizinischen Abfällen und pharmazeutischer Verpackung. Die Initiative zielt darauf ab, Dekarbonisierungslösungen zu identifizieren und zu testen, die im gesamten Gesundheitsökosystem geteilt werden können. BMC wird Abfall-Audits in klinischen Bereichen durchführen, um Emissionshotspots zu identifizieren und neue Technologien zu testen. Diese Partnerschaft unterstützt das Ziel von Takeda, bis 2035 netto null Emissionen in den Betriebsabläufen und bis 2040 in der gesamten Wertschöpfungskette zu erreichen, was kürzlich von der Initiative Science Based Targets validiert wurde.

Positive
  • Partnership aligns with Takeda's validated net-zero emissions goals for 2035 (operations) and 2040 (value chain)
  • Collaboration with leading environmental excellence hospital BMC enhances sustainability initiatives
  • Potential for cost reduction through waste management optimization
Negative
  • Implementation of new waste management systems may require significant investment
  • Regulatory compliance requirements could limit decarbonization options

Insights

This collaboration between Takeda and Boston Medical Center represents an innovative step in healthcare decarbonization, but lacks immediate financial materiality. While the initiative to reduce emissions from medical waste and pharmaceutical packaging aligns with Takeda's validated 2035 and 2040 net-zero goals, the three-year research project's direct impact on operations and financial performance will be minimal in the near term.

The partnership demonstrates strong ESG commitment and could yield long-term cost benefits through waste reduction and improved operational efficiency. However, without specific investment figures or quantifiable targets, the immediate market impact is The focus on sharing best practices suggests this is more about industry leadership and knowledge development than direct financial returns.

  • First-of-its-Kind Research Collaboration for Takeda and Boston Medical Center with the Aim to Decarbonize the Health Care Value Chain
  • Three-Year Collaboration to Tackle Carbon Emissions from Regulated Medical Waste, Including Pharmaceutical Packaging
  • Learnings will be Shared to Scale Decarbonization Solutions Across the Health Care Value Chain

CAMBRIDGE, Mass. & BOSTON--(BUSINESS WIRE)-- Takeda (TOKYO:4502/NYSE:TAK) and Boston Medical Center (BMC) today announced a new collaboration focused on identifying innovative solutions that can reduce hard-to-abate greenhouse gas (GHG) emissions in the health care sector. The collaboration between Takeda and BMC aims to reduce the GHG emissions caused by disposal of regulated medical waste, such as pharmaceutical packaging and single-use plastics, which are among the most difficult environmental challenges facing the industry. The effort will also seek to scale the interventions developed through the collaboration by sharing best practices to help other organizations adopt and learn new ways to decarbonize in their operations to drive wider health care ecosystem impact.

“At BMC, as a national leader in environmental excellence, we have long recognized that sustainability is health care,” said Robert Biggio, Senior Vice President and Chief Sustainability & Real Estate Officer at Boston Medical Center Health System. “Increasing health risks exacerbated by climate change, such as extreme heat, pollution, biodiversity loss and other environmental impacts are a real and direct threat to patient and community wellbeing. Our collaboration with Takeda aims to drive meaningful change by tackling environmental challenges that contribute to health disparities in many communities. This collaboration is a critical step in driving innovation in the medical supply chain that can be shared with other health care organizations for a healthier environment for all communities.”

A key objective of this collaboration is to effectively identify, pilot and share valuable insights on decarbonization solutions that other healthcare organizations can adopt as they also seek to reduce greenhouse gas emissions. This may include engaging with other industry stakeholders, such as suppliers, waste vendors, and packaging providers to share and establish new best practices and practical applications.

As a part of this collaboration, Boston Medical Center will conduct waste audits across key clinical areas to identify emission hotspots and pilot new technologies aimed at reducing emissions from the disposal of regulated medical waste, including pharmaceutical packaging. BMC, recognized with multiple Practice Greenhealth Top 25 Environmental Excellence Awards, is the first hospital in the nation to leverage a rooftop solar array to provide energy bill credit to eligible patients facing energy insecurity. The hospital built two rooftop farms supplying fresh produce for the hospital's food pantry, patient meals and local community organizations, and opened the first net-zero ready for energy behavioral health facility—among other leading initiatives. BMC was also the first nonprofit health care organization in the country to issue sustainability bonds with a $232 million bond sale for campus renovations to better support patient care.

“Takeda understands the undeniable connection between human and planetary health,” said Teresa Bitetti, president of Takeda’s global oncology business unit. “To help us develop solutions and tackle some of the most difficult environmental challenges the health care industry is facing, we need bold collaborations with organizations like BMC. We are proud to partner with BMC, an organization that shares our commitment to advancing environmental sustainability, improving patient health and supporting innovations across the broader healthcare ecosystem.”

For Takeda, this collaboration supports its ambitious climate goal to reach net-zero greenhouse gas (GHG) emissions in its operations by 2035 and across our value chain by 2040. In 2024, the Science Based Targets initiative (SBTi) validated Takeda’s net zero GHG emission goals as being consistent with reductions required to limit the rise in global temperature to 1.5°C above pre-industrial levels.

About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. We serve patients in approximately 80 countries and regions driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

About Boston Medical Center
Boston Medical Center models a new kind of excellence in healthcare, where innovative and equitable care empowers all patients to thrive. We combine world-class clinicians and cutting-edge treatments with compassionate, quality care that extends beyond our walls. As an award-winning health equity leader, our diverse clinicians and staff interrogate racial disparities in care and partner with our community to dismantle systemic inequities. And as a national leader in research and the teaching affiliate for Boston University Chobanian & Avedisian School of Medicine, we’re driving the future of care.

Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Takeda Media Relations:

media_relations@takeda.com

BMC Media Relations:

communications@bmc.org

Source: Takeda Pharmaceutical Company Limited

FAQ

What are Takeda's (TAK) net-zero emission targets?

Takeda (TAK) aims to achieve net-zero greenhouse gas emissions in operations by 2035 and across its value chain by 2040, as validated by the Science Based Targets initiative.

What is the focus of Takeda's (TAK) collaboration with Boston Medical Center?

The collaboration focuses on reducing greenhouse gas emissions from regulated medical waste, including pharmaceutical packaging and single-use plastics, while developing shareable decarbonization solutions for the healthcare sector.

How long is the decarbonization partnership between Takeda (TAK) and Boston Medical Center?

The collaboration between Takeda (TAK) and Boston Medical Center is a three-year partnership focused on reducing greenhouse gas emissions in healthcare.

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of

NYSE:TAK

TAK Rankings

TAK Latest News

TAK Stock Data

42.15B
3.17B
0.01%
2.45%
0.19%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Tokyo